SLC5A2 and heart failure: SGLT2 inhibitors reduced MACE but the effect on components is neutral Reduced heart failure hospitalization, CV mortality, and the composite renal endpointMeta-analyses for patients ≥75 years yielded similar results.Weight loss (visceral fat loss) [226] SBP reduction [227]